Medical News
Safety and Immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) V...
Lancet HIV
n this study of people with HIV, ChAdOx1 nCoV-19 was safe and Immunogenic, supporting vaccination for those well...
22 Jun 2021
High Prevalence of NRTI and NNRTI Drug Resistance Among ART-...
J. Acquir. Immune Defic. Syndr.
Many hospitalized, ART-experienced patients with advanced HIV were on an ineffective first-line regimen. Addressing...
16 Jun 2021
Adipokines, Weight Gain and Metabolic and Inflammatory Marke...
Clin. Infect. Dis.
Higher circulating leptin is associated with greater HOMA-IR and hsCRP independent of fat depot size, suggesting...
15 Jun 2021
Time to Viral Rebound After Interruption of Modern Antiretro...
Clin Infect. Dis.
Early ART initiation, using either older or newer ART regimens, was associated with a significant delay in the time...
14 Jun 2021
eCMEs
Key Trials
AMBER and EMERALD Trial: 96-week Resistance Analysis of Once-daily Single Tablet Regimen of D/C/F/TAF in HIV-1 Adults Patients
The present study is a 96-week resistance analysis of AMBER and EMERALD trials, evaluating efficacy and safety of darunavir/cobicistat/emtricitabine...
Benefits of Inhaled Budesonide in Early COVID-19 Infection: STOIC Study
This infographic summarises the key points of the STOIC study and outlines the benefits of administering inhaled budesonide in early COVID-19...
48-week Efficacy and Safety of Switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide in Virologically Suppressed People Living with HIV aged > 65 years
The presents study evaluated efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)....
Efficacy of Reduced Doses of both TDF and EFV for the Treatment of HIV-1 Infection
This study is the first randomized, controlled trial in an antiretroviral-naive population that evaluated the efficacy of reduced doses of both...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6